CD274 and non-small cell lung carcinoma: In addition, the systematic review by Pillai et al. comparing the toxicity profile of PD‐1 versus PD‐L1 showed that overall and grade 3–5 AEs related to treatment with PD‐1 and PD‐L1 inhibitors were similar (P > 0.05).13 Our study was undertaken to compare the efficacy of PD‐1 and PD‐L1 inhibitors for the treatment of NSCLC.